Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection

Exclusion Criteria

• •Prior exposure to an direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase
• •Pregnant or nursing female, or male with pregnant female partner
• •Current or prior history of clinical hepatic decompensation
• •History of clinically-significant illness or any other major medical disorder that may have interfered with subject treatment, assessment, or compliance with the protocol
• •Excessive alcohol ingestion or significant drug abuse